Abstract
The NOCTET (NOrdic Certican Trial in HEart and lung Transplantation) trial demonstrated that everolimus improves renal function in maintenance thoracic transplant (TTx) recipients. Nevertheless, introduction of everolimus is not recommended for patients with advanced renal failure. We evaluated NOCTET data to assess everolimus introduction amongst TTx recipients with advanced renal failure.
| Originalsprog | Engelsk |
|---|---|
| Tidsskrift | Journal of Heart and Lung Transplantation |
| Vol/bind | 31 |
| Udgave nummer | 3 |
| Sider (fra-til) | 259-65 |
| Antal sider | 7 |
| ISSN | 1053-2498 |
| DOI | |
| Status | Udgivet - 2012 |
Fingeraftryk
Dyk ned i forskningsemnerne om 'Improvement in renal function after everolimus introduction and calcineurin inhibitor reduction in maintenance thoracic transplant recipients: the significance of baseline glomerular filtration rate'. Sammen danner de et unikt fingeraftryk.Citationsformater
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS